UNLABELLED: Measured human dosimetry of the (68)Ga-labeled synthetic somatostatin analog (68)Ga-DOTATATE has not been reported in the peer-reviewed literature. (68)Ga-DOTATATE is an investigational PET/CT imaging agent that binds with high affinity to somatostatin receptor subtype 2, found on many human cancers, most classically neuroendocrine tumors but also others. Reporting of measured dosimetry of (68)Ga-DOTATATE could be useful for investigations for diagnosis, staging, and restaging of somatostatin receptor-expressing tumors. METHODS: We performed measured dosimetry with (68)Ga-DOTATATE PET/CT scanning in 6 volunteer human subjects as part of an Institutional Review Board-approved biodistribution investigation of the use of this radiopharmaceutical for possible future use in the diagnosis of indeterminate lung nodules or lung cancer. Five subjects were imaged at 3 time points, and 1 subject was imaged at 2 time points. Dosimetry was then measured for the whole body and for specific organs. RESULTS: There were no observed adverse events to the radiopharmaceutical in the immediate or delayed time frames, with a follow-up of 1 y. One patient had stage IV non-small cell lung cancer and remains alive but with disease progressing on treatment. For the other 5 patients, it was ultimately proven that they had benign nodules. The measured dosimetry shows that the critical organ with (68)Ga-DOTATATE is the spleen, followed by the uroepithelium of the bladder, the kidneys, and the liver, in that order. Organ-specific and whole-body dosimetries for (68)Ga-DOTATATE were similar to but often slightly greater than those for (68)Ga-DOTATOC or (68)Ga-DOTANOC but less than those for (111)In-diethylenetriaminepentaacetic acid-octreotide. CONCLUSION: No toxicity was observed in our 6 patients, and no adverse events occurred. The measured human dosimetry of (68)Ga-DOTATATE is similar to that of other (68)Ga-labeled somatostatin receptor analogs.
UNLABELLED: Measured human dosimetry of the (68)Ga-labeled synthetic somatostatin analog (68)Ga-DOTATATE has not been reported in the peer-reviewed literature. (68)Ga-DOTATATE is an investigational PET/CT imaging agent that binds with high affinity to somatostatin receptor subtype 2, found on many humancancers, most classically neuroendocrine tumors but also others. Reporting of measured dosimetry of (68)Ga-DOTATATE could be useful for investigations for diagnosis, staging, and restaging of somatostatin receptor-expressing tumors. METHODS: We performed measured dosimetry with (68)Ga-DOTATATE PET/CT scanning in 6 volunteer human subjects as part of an Institutional Review Board-approved biodistribution investigation of the use of this radiopharmaceutical for possible future use in the diagnosis of indeterminate lung nodules or lung cancer. Five subjects were imaged at 3 time points, and 1 subject was imaged at 2 time points. Dosimetry was then measured for the whole body and for specific organs. RESULTS: There were no observed adverse events to the radiopharmaceutical in the immediate or delayed time frames, with a follow-up of 1 y. One patient had stage IV non-small cell lung cancer and remains alive but with disease progressing on treatment. For the other 5 patients, it was ultimately proven that they had benign nodules. The measured dosimetry shows that the critical organ with (68)Ga-DOTATATE is the spleen, followed by the uroepithelium of the bladder, the kidneys, and the liver, in that order. Organ-specific and whole-body dosimetries for (68)Ga-DOTATATE were similar to but often slightly greater than those for (68)Ga-DOTATOC or (68)Ga-DOTANOC but less than those for (111)In-diethylenetriaminepentaacetic acid-octreotide. CONCLUSION: No toxicity was observed in our 6 patients, and no adverse events occurred. The measured human dosimetry of (68)Ga-DOTATATE is similar to that of other (68)Ga-labeled somatostatin receptor analogs.
Authors: Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti Journal: Eur J Nucl Med Mol Imaging Date: 2010-10 Impact factor: 9.236
Authors: Alexander R Haug; Christoph J Auernhammer; Björn Wängler; Gerwin P Schmidt; Christopher Uebleis; Burkhard Göke; Paul Cumming; Peter Bartenstein; Reinhold Tiling; Marcus Hacker Journal: J Nucl Med Date: 2010-08-18 Impact factor: 10.057
Authors: Linda Villard; Anna Romer; Nicolas Marincek; Philippe Brunner; Michael T Koller; Christian Schindler; Quinn K T Ng; Helmut R Mäcke; Jan Müller-Brand; Christoph Rochlitz; Matthias Briel; Martin A Walter Journal: J Clin Oncol Date: 2012-03-05 Impact factor: 44.544
Authors: Andreas Pfeifer; Ulrich Knigge; Jann Mortensen; Peter Oturai; Anne Kiil Berthelsen; Annika Loft; Tina Binderup; Palle Rasmussen; Dennis Elema; Thomas Levin Klausen; Søren Holm; Eric von Benzon; Liselotte Højgaard; Andreas Kjaer Journal: J Nucl Med Date: 2012-07-10 Impact factor: 10.057
Authors: Heribert Hänscheid; Reinhart A Sweeney; Michael Flentje; Andreas K Buck; Mario Löhr; Samuel Samnick; Michael Kreissl; Frederik A Verburg Journal: Eur J Nucl Med Mol Imaging Date: 2012-04-20 Impact factor: 9.236
Authors: C Pettinato; A Sarnelli; M Di Donna; S Civollani; C Nanni; G Montini; D Di Pierro; M Ferrari; M Marengo; C Bergamini Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-14 Impact factor: 9.236
Authors: H Hartmann; K Zöphel; R Freudenberg; L Oehme; M Andreeff; G Wunderlich; G Eisenhofer; J Kotzerke Journal: Nuklearmedizin Date: 2009-07-28 Impact factor: 1.379
Authors: Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning Journal: J Clin Oncol Date: 2008-05-01 Impact factor: 44.544
Authors: Martijn van Essen; Eric P Krenning; Boen L R Kam; Marion de Jong; Roelf Valkema; Dik J Kwekkeboom Journal: Nat Rev Endocrinol Date: 2009-06-02 Impact factor: 43.330
Authors: Shadi A Esfahani; Stephanie Salcedo; Pedram Heidari; Onofrio A Catalano; Rachel Pauplis; Jacob Hesterman; James F Kronauge; Umar Mahmood Journal: Am J Nucl Med Mol Imaging Date: 2017-04-15
Authors: Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile Journal: Eur J Nucl Med Mol Imaging Date: 2018-10 Impact factor: 9.236
Authors: Thomas A Hope; Emily K Bergsland; Murat Fani Bozkurt; Michael Graham; Anthony P Heaney; Ken Herrmann; James R Howe; Matthew H Kulke; Pamela L Kunz; Josh Mailman; Lawrence May; David C Metz; Corina Millo; Sue O'Dorisio; Diane L Reidy-Lagunes; Michael C Soulen; Jonathan R Strosberg Journal: J Nucl Med Date: 2017-10-12 Impact factor: 10.057
Authors: Anders Josefsson; Robert F Hobbs; Sagar Ranka; Bryan C Schwarz; Donika Plyku; Jose Willegaignon de Amorim de Carvalho; Carlos Alberto Buchpiguel; Marcelo Tatit Sapienza; Wesley E Bolch; George Sgouros Journal: J Nucl Med Date: 2018-02-09 Impact factor: 10.057
Authors: Samira M Sadowski; Vladimir Neychev; Corina Millo; Joanna Shih; Naris Nilubol; Peter Herscovitch; Karel Pacak; Stephen J Marx; Electron Kebebew Journal: J Clin Oncol Date: 2015-12-28 Impact factor: 44.544
Authors: James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier Journal: Pancreas Date: 2017-07 Impact factor: 3.327